Profile



GenChem & GenPharm (Changzhou) Co., Ltd. is a sino-foreign joint venture which serves for the global pharmaceutical market with technology innovation. The company is founded in 2005, located in Binjiang Industrial Park in Changzhou Jiangsu Province, close to Shanghai-Nanjing Expressway, Beijing -Shanghai Expressway and Changzhou Port. Our 1st phase investment construction has finished in 2007, and 2rd phase of investment construction has finished in 2015, now covers an area of 122 acres. 


We commit to R&D and scale production of pharmaceuticals, agricultures and other intermediates, unique products chain from R&D, production to sales has been formed. We posses Grignard reaction, phosgenation reation, selective cyanide reaction and some other core technology with patented technology  of scale production of the use of metal sodium, metal potassium and mature experience. We have specialized workshop, strict quality management system and Complete tri-waste management system.


We focous on R&D, production and sales of alkali metal alkyloxides, amino acid protection agents, protected amino acids and other anti-cancer, anti viral drugs intermediates, as well as key intermediates of the world's leading edge of biological pharmaceutical peptide compounds. The capacity of alkali metal alkoxides, amino acid protection agents and protected amino acids are the biggest in the world, the global market share is over 50%, the domestic market share is over 70%.Our main products include STB, KTB, DIBOC,  BOC/FMOC/MOC/CBZ protected amino acids, ortho ester series products. Our products also exported to the US, Europe, Japan, Korea, India and so on, besides serving the domestic high-end market.

Currently we own about 400 employees, carry out modern enterprise management system, obtain ISO9001:2008 and ISO14001:2004. Providing cost-effective products and service to all clients is our persistent pursuit.

Our company attaches great importance to workers health, production safety, environmental protection, which is considered to our prerequisite social responsibility. We emphasis on team-work and technology innovation, and get many invention patents and utility model patents every year. In the future,  the company will increase investment in independent R&D, and constantly develop advance pharmaceutical intermediates, to the downstream industry chain extension, and connect with the global pharmaceutical industry, especially peptides, to build  a beautiful new life is our promise.